Dioscure Therapeutics SE Overview
Company Headquarters: Bonn, Germany
Founded: 2020
Workforce: ~10
Company Working: Dioscure Therapeutics SE is the fastest growing next-generation immunotherapies company which is involved in the development of SARS-CoV-2. The company developed bi- and trivalent variable domains of heavy chain-only antibodies (VHHs) are synergetic amalgamations of single-domain antibodies for the treatment of various infected diseases. The company designed lead candidates which target two separate epitopes of the SARS-CoV-2 spike protein with the potential to be highly efficacious, well-tolerated, and manufactured at a large-scale standardized process. The company has a strong business presence in the Europe region.
Strategy
Dioscure Therapeutics SE emphasizes R&D productivity while maximizing the value of its current brands and in-line portfolio. Also, the company focuses on expanding its existing product portfolio through future organic growth. It aims to achieve stable earnings and sound financing, through long-term and sustainable, successful development forms. By collaborating with new companies, the company intends to develop nanobody products and technologies to amplify the benefits of its core products.
